She also plays a key role in how CSL continues to evolve its Finance organization and drive greater efficiencies across the company’s Enabling Functions and operating model. Her accountabilities include financial planning, reporting, capital management, tax, treasury, investor relations and leading the global Finance function. In this role, Joy is responsible for managing the financial aspects of CSL’s strategy and serves as the company’s chief financial steward. Joy Linton was named Chief Financial Officer in October 2020 and leads the Global Finance organization, including both the CSL Behring and Seqirus businesses, and its accompanying strategy. Greg received his Juris Doctor degree from the University of Southern California in 1987 and his bachelor’s degree, cum laude, in Finance and Business Economics from the University of Southern California School of Business in 1983. Before that, he worked 10 years in private practice, focusing on corporate and securities law, mergers and acquisitions, corporate finance and commercial transactions. Prior to joining CSL, Greg served as Vice President and Senior Counsel for CB Richard Ellis International, a global real estate and financial services firm. In 2017, Greg received the Legends in Law award presented by the Burton Foundation.
#Xerion pharmaceuticals ag moneyhouse professional
In addition, Greg is responsible for Risk Management, Compliance and Corporate Communications.Īmong his industry recognitions as a global leader, Greg received the World Recognition of Distinguished General Counsel from the Directors Roundtable in 2016 in acknowledgment of his professional accomplishments and passion for ethical leadership. Greg is based in King of Prussia, Pennsylvania, and oversees legal operations globally. In January 2009, Greg was appointed to the role of Group General Counsel for CSL Limited, an Australian Stock Exchange-listed company headquartered in Melbourne, Australia. In this role, he was instrumental in the company’s acquisition and integration of industry competitor Aventis Behring, and upon the integration of the two companies in 2004, Greg assumed the global General Counsel position for the combined business. General Counsel for CSL’s sales and distribution business, ZLB Bioplasma. He is a member of the Executive Global Leadership Group, and he serves as Secretary to the Board’s Audit and Risk Management Committee. CSL is a global biotechnology leader with business operations in more than 60 countries, and Greg has served as Group General Counsel since 2009.
Greg Boss is responsible for worldwide legal operations for all CSL Limited Group companies. in Chemical Engineering from Carnegie Mellon University. in Chemical Engineering from the University of Pennsylvania and a Ph.D. He has served on numerous professional and academic boards, most recently the Board of Trustees on the Illinois Institute of Technology and the Society for Biological Engineering. He also served in a range of progressively senior level roles in R&D and manufacturing at Johnson & Johnson, Bristol-Myers Squibb and Merck.ĭr. McKenzie was Executive Vice President of Pharmaceutical Operations & Technology at Biogen. He transformed CSL's global end-to-end operations, advanced CSL Seqirus' differentiated portfolio strategy, and led CSL Plasma through COVID-19 challenges while surpassing plasma collection volumes beyond pre-pandemic levels.
McKenzie became accountable for optimising CSL's operations as well as growing the CSL Seqirus, CSL Plasma, and CSL Vifor businesses. McKenzie has more than 30 years of leadership experience in the global biotechnology industry, including managing complex organisations through compelling growth and transformation.Īfter joining CSL as Chief Operating Officer in 2019, Dr. Paul McKenzie was appointed Chief Executive Officer and Managing Director of CSL on 6 March 2023.ĭr.
0 kommentar(er)
